Related Experiment Video
Updated: Jun 4, 2026

Investigation of Beige Fat Biology and Metabolism Using the CRISPR SunTag-p65-HSF1 Activation System
Published on: January 6, 2023
AAV-mediated FGF21 gene therapy promotes health span extension by whole-body tissue-specific adaptations
Veronica Jimenez1, Victor Sacristan1, Miquel Garcia1
1Center of Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Abstract:
The decline of organ function during aging limits health span. Despite the potential of lifestyle interventions to improve health, sustained maintenance of health span is challenging, and no gerotherapeutic drugs have been approved. Here, we demonstrated that aged and geriatric male and female mice treated with muscle-directed adeno-associated viral (AAV) vector-mediated fibroblast growth factor 21 (FGF21) gene therapy extended health span and lifespan with sustained organ benefits. This treatment normalized body weight and adiposity, improved insulin sensitivity and glucose homeostasis, preserved hepatic detoxification capacity, counteracted age-related kidney disease, promoted cardiac health and muscular function, and enhanced cognition. Transcriptomic and histopathological analyses indicated improved whole-body energy homeostasis and cellular fitness, which were mediated by tissue-specific adaptations, including enhanced mitochondrial function, restored proteostasis, and reversion of inflammation, fibrosis, and amyloidosis. AAV-FGF21 treatment also activated AMPK signaling. These results highlight FGF21 gene therapy as a potential strategy to promote health span and delay age-related deterioration.
Insights
Muscle-directed fibroblast growth factor 21 (FGF21) gene therapy in aged mice improved healthspan and lifespan. This intervention normalized body weight, enhanced organ function, and boosted cognition, offering a potential gerotherapeutic strategy.
Area of Science:
- Aging research
- Gene therapy
- Metabolic diseases
Background:
- Organ function decline limits healthspan in aging.
- Lifestyle interventions show potential but sustained healthspan maintenance is difficult.
- No gerotherapeutic drugs are currently approved.
Purpose of the Study:
- To investigate the efficacy of muscle-directed adeno-associated viral (AAV) vector-mediated fibroblast growth factor 21 (FGF21) gene therapy in aged mice.
- To assess the impact of AAV-FGF21 on healthspan, lifespan, and organ function.
- To explore the underlying molecular mechanisms of AAV-FGF21 treatment.
Main Methods:
- Administration of muscle-directed AAV-FGF21 gene therapy to aged and geriatric male and female mice.
- Assessment of various physiological parameters including body weight, adiposity, insulin sensitivity, glucose homeostasis, hepatic detoxification, kidney function, cardiac health, muscle function, and cognition.
- Transcriptomic and histopathological analyses to evaluate whole-body energy homeostasis, cellular fitness, mitochondrial function, proteostasis, inflammation, fibrosis, and amyloidosis.
- Investigation of AMPK signaling pathway activation.
Main Results:
- AAV-FGF21 treatment extended healthspan and lifespan in aged mice.
- The therapy normalized body weight and adiposity, improved insulin sensitivity and glucose homeostasis.
- Significant improvements were observed in hepatic detoxification, kidney health, cardiac function, muscle strength, and cognitive performance.
- Transcriptomic and histopathological analyses revealed enhanced energy homeostasis and cellular fitness, with restored mitochondrial function, proteostasis, and reduced inflammation, fibrosis, and amyloidosis.
- AMPK signaling was activated by AAV-FGF21 treatment.
Conclusions:
- Muscle-directed FGF21 gene therapy is a promising strategy to extend healthspan and lifespan.
- This approach effectively counteracts age-related physiological decline and improves multiple organ functions.
- FGF21 gene therapy demonstrates potential as a gerotherapeutic intervention by improving whole-body energy homeostasis and cellular resilience.
Related Concept Videos
Gene Therapy
Gene Therapy
Whole Body Regeneration
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
The Effect of Aging on Tissues
